• Interim CEO employment contract consists solely of equity compensation • Samir R. Patel, M.D., increases ownership to 14.2% with $1.25m …
Press Release
Akari Therapeutics Secures $7.6 Million in Upsized Financing Round
BOSTON and LONDON – June 4, 2024 (GLOBE NEWSWIRE) – Akari Therapeutics Plc (Nasdaq: AKTX), an innovative biotechnology company advancing therapies for …
[Read more...] about Akari Therapeutics Secures $7.6 Million in Upsized Financing Round
Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights
BOSTON and LONDON, May 16, 2024 (GLOBE NEWSWIRE) – Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for …
Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics
BOSTON and LONDON, May 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing advanced therapies for autoimmune …
[Read more...] about Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics
Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity
BOSTON and PLEASANTON, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX, “Akari”) and Peak Bio Inc. (OTC: PKBO, “Peak”) today …